Pharmacogenetic analysis of inter-ethnic variability in the uptake transporter SLCO1B1 gene in colombian, mozambican, and portuguese populations by Nega, Mulata Haile
UNIVERSIDADE DO ALGARVE
FACULDADE DE CIÊNCIAS E TECNOLOGIA
PHARMACOGENETIC ANALYSIS OF INTER-ETHNIC VARIABILITY
IN THE UPTAKE TRANSPORTER SLCO1B1 GENE IN COLOMBIAN,
MOZAMBICAN, AND PORTUGUESE POPULATIONS
MULATA HAILE NEGA
FARO, PORTUGAL
2019
UNIVERSITY OF ALGARVE
PHARMACOGENETIC ANALYSIS OF INTER-ETHNIC VARIABILITY IN THE
UPTAKE TRANSPORTER SLCO1B1 GENE IN COLOMBIAN, MOZAMBICAN, AND
PORTUGUESE POPULATIONS
Mulata Haile Nega
Dissertação / Dissertation
Mestrado Erasmus Mundus em Inovação Quimica e Regulamentação
(Erasmus Mundus Master in Chemical Innovation and Regulation)
Trabalho efetuado sob a orientação de:
Work supervised by:
Vera Linda Ribeiro Marques (PhD)
2019
II
DECLARATION OF AUTHORSHIP
I declare that I am the author of this work, which is original. The work cites other authors and
works, which are adequately referred in the text and are listed in the bibliography.
Mulata Haile Nega
Copyright: (Mulata Haile Nega). The (University of Algarve) has the right to keep and publicise
this work through printed copies in paper of digital form, or any other means of reproduction, to
disseminate it in scientific repositories and to allow its copy and distribution with educational
and/or research objectives, as long as they are non-commercial and give credit to the author and
editor.
III
ACKNOWLEDGEMENTS
First and foremost, Thanks be to GOD, the Almighty, and creator of the Universe and all Wisdoms,
for his indescribable gift and letting me to be who I am now.
I would like to thank my supervisor Professor Vera Linda Ribeiro Marques, from
Pharmacogenomics and Molecular Toxicology Laboratory, faculty of Science and Technology,
Universidad do Algarve, Portugal, for her guidance and kind full support and motivation
throughout the work.
I am most grateful to the Erasmus+ program of the European Union, EMMC ChIR, which offered
me the opportunity to pursue this study with full scholarship allowance.
Finally, I would like to give my gratitude to my sisters, spiritual brothers and friends for
unconditional love, support and encouragement during these years.
This study has received a grant from Portuguese national funds from FCT - Foundation for Science
and Technology through projects UID/Multi/04326/2019 and UID/BIM/04773/2013, and was
developed in the context of the Network for Research in Tropical Health in CPLP countries and
the Iberoamerican Network of Pharmacogenetics and Pharmacogenomics (CYTED).
IV
I dedicate this thesis
to my Mother and my Sisters
VRESUMO
As atividades de enzimas metabólicos e transportadores de fármacos determinam, em larga
medida, a resposta ao fármaco e a sua eliminação. A etnia é uma variável demográfica importante
que contribui para a variabilidade interindividual no metabolismo e transporte de fármacos. Como
resultado de diferenças étnicas na prevalência de polimorfismos de nucleótido único (SNP), pode
ocorrer maior risco de eventos adversos, falha do tratamento ou prevalência de patologias em
algumas populações. Os transportadores de influxo são um dos principais factores que contribuem
para o processo de eliminação de fármacos. Foi demonstrado que os genes que codificam esses
transportadores de influxo são polimórficos. O OATP1B1 é um transportador de influxo conhecido
por mediar a captação de vários compostos endógenos e xenobióticos. Várias variantes foram
descritas no gene SLCO1B1 que codifica o OATP1B1. Entre estas, a variante mais estudada,
c.521T> C, foi descrita como estando significativamente associada ao risco de miopatias induzidas
pela terapêutica com estatinas. Apesar da clara relevância clínica desta variante polimórfica, um
número reduzido de populações foram caracterizadas. Até o momento, não existem dados
epidemiológicos para a variante SLCO1B1 c.521T> C nas populações colombiana, moçambicana
e portuguesa.
Este estudo teve, assim, como objetivo, avaliar as frequências genotípicas e alélicas da variante
SLCO1B1 c.521T> C em voluntários saudáveis colombianos, moçambicanos e portugueses. O
DNA genómico isolado de amostras de sangue obtidas, sob consentimento informado, de 67
indivíduos colombianos, 53 moçambicanos e 61 portugueses foi analisado para este polimorfismo
através de um novo método de genotipagem por PCR-RFLP.
Um total de 47 (70,15%), 12 (17,91%) e 8 (11,94%) dos 67 indivíduos colombianos, 47 (88,68%),
5 (9,43%), 1 (1,89%) dos 53 indivíduos moçambicanos e 40 (65,57%), 16 (26,23%), 5 (8,20%),
dos 61 indivíduos portugueses eram portadores do genótipo T / T-homo, C / T-hetero e C / C-
homozigota, respectivamente . Em termos de frequências alélicas, observou-se um total de 106
alelos T (79,1%) e 28 alelos C (20,9%) em indivíduos colombianos; 99 alelos T (93,4%) e 7 alelos
C (6,6%) C em moçambicanos e 96 alelos T (78,7%) e 26 alelos C (21,3%) em indivíduos
portugueses. As frequências observadas em moçambicanos mostram uma diferença
estatisticamente significativa em relação às observadas em colombianos (p=0,0017) e portugueses
(p=0,0022). Por outro lado, as frequências observadas na amostra da população colombiana não
são significativamente diferentes (p=1.000) em relação às observadas em Portugal.
Em conclusão, os nossos dados demonstraram que o genótipo homozigota T / T é altamente
prevalente, o genótipo homozigota variante, C / C, apresenta a menor frequência em
moçambicanos, sendo por outro lado relativamente frequente em populações colombianas e
portuguesas. Como resultado, indivíduos (principalmente caucasianos) com o genótipo
homozigótico variante c.521C/C podem ser altamente suscetíveis a efeitos adversos relacionados
à estatina do que aqueles com o genótipo c.521TT (referência) para o SNP c.521T> C.
Palavras-chave; SNP, SLCO1B1, estatinas, transportadores de influxo
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ABSTRACT
The activities of drug metabolizing enzymes and transporters greatly determine drug disposition
and response. Ethnicity is an important demographic variable contributing to inter-individual
variability in drug metabolism and transport. Influx transporters are one of the key contributors to
the process of drug disposition. It has been demonstrated that the genes coding for these influx
transporters are polymorphic. OATP1B1 is an influx transporter known to mediate the uptake of
various endogenous compounds and xenobiotics. Several sequence variations have been
discovered in the SLCO1B1 gene encoding OATP1B1. Statin-induced myopathy is reported to be
significantly associated with the c.521T>C polymorphism. To date, there is no
SLCO1B1 c.521T>C epidemiologic data for the Colombian, Mozambican and Portuguese
populations.
Therefore, this study aimed at assessing the genotype and allele frequencies of
the SLCO1B1 c.521T>C variant in Colombian, Mozambican and Portuguese healthy volunteers.
Genomic DNA isolated from blood samples obtained from 67 Colombian, 53 Mozambican and 61
Portuguese healthy individuals under informed consent was analyzed for the SLCO1B1 c.521T>C
polymorphism using a novel PCR-RFLP genotyping method. A total of 47 (70.15%), 12 (17.91%)
and 8 (11.94%) out of 67 Colombian individuals, 47(88.68%), 5(9.43%), 1(1.89%) out of 53
Mozambican individuals, and  40(65.57%), 16(26.23%), 5(8.20%), out of 61 Portuguese
individuals were SLCO1B1 c.521T>C T/T-homo (reference), C/T-hetero, and C/C-homozygote
genotypes, respectively. And the allelic frequency of the populations shows a total of 106 (79.1%)
T and 28 (20.9%) C alleles of Colombian individuals, 99 (93.4%) T and 7 (6.6%) C alleles of
Mozambican, and 96 (78.7%) T and 26 (21.3%) C alleles of Portuguese individuals. The frequency
observed in Mozambicans shows statistically significant difference from the ones observed in
Colombians (p=0.0017) and Portuguese (p=0.0022). Whereas the frequency observed in
Colombians was not statistically significant (p=1.000) from the ones observed in Portugal.
In conclusion, our data demonstrated that the homozygote T/T genotype is highly prevalent, and
the homozygote C/C variant is very less frequent in Mozambicans, whereas the homozygote C/C
variant was relatively frequent in Colombians and Portuguese populations. As a result, subjects
(mainly Caucasians) with the homozygous variant c.521CC genotype may be highly susceptible
to statin related adverse effects than those with the c.521TT genotype of the c.521T>C SNP.
Key words; SNP, SLCO1B1, statins, influx transporters
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11. INTRODUCTION
Genetics is a biological science that studies heredity. The passing on of traits from parents to their
offspring; either through asexual reproduction or sexual reproduction is known as heredity. The
offspring cells or organisms get the genetic information from their parents. Variations among
individuals can accumulate and cause species to evolve by natural selection. Inherited traits are
controlled by genes and the complete set of genes within an organism's genome is called
its genotype (Pearson, 2006).
The interaction of the genotypes with the environment leads to the development of these traits
(Visscher, et al., 2008). Consequently, many features of an organism's phenotype are not inherited.
For example, the interaction between a person's phenotype and sunlight results in a suntanned skin
(Shoag, et al., 2013). Thus, suntans are not passed on to people's children. However, due to
differences in their genotype, some people tan more easily than others as in the case of inherited
trait of albinism who do not tan at all and are very sensitive to sunburn (Pho & Leachman, 2010).
The nucleus of each human somatic cell carries 46 chromosomes: two copies of each of the 22
autosomal chromosomes, and either two copies of the X-chromosome (in females), or one copy
each of the X and Y chromosomes (in males). Each cell also contains numerous mitochondria,
which have their own ˜16 kb (kilobase pair) genome (Oetting, et al., 1996), (Lander, et al., 2001),
(Venter, et al., 2001).
DNA (Deoxyribonucleic Acid) is a complex double stranded molecule composed of four different
nucleotides linked by phosphate diester covalent bonds, associated with histone proteins, that
encodes genetic information by which heritable traits are known to be passed from one generation
to the next (Pearson, 2006); whereas a gene is a portion of DNA molecule that specifies a single
functional unit. Genes are different by their sequences of bases. The condensed structures of long
DNA molecules within a cell are called chromosomes. The genetic material is therefore inherited
from parents in the form of homologous chromosomes that contains a distinct combination of
DNA sequences that code for genes. The specific site of a DNA sequence within a chromosome is
known as a locus. In other words, the term locus refers to the chromosomal location of a gene or
DNA marker. If the DNA sequence at a specific locus varies among individuals, the different
forms of this sequence are called alleles. Mutations can change DNA sequences, producing new
alleles. The new allele produced by a mutation within a gene may affect the trait that the gene
controls, modifying the phenotype of the organism (Futuyma, 2005).
2A single copy of the human nuclear genome (one copy each of chromosomes 1-22, X and Y) is
3.2 gigabase pairs in length and has been estimated to contain approximately 30,000–35,000
protein-coding genes; approximately 1.5% of our DNA is protein-coding sequence, hidden within
a large excess of non-coding DNA (Lander, et al., 2001) (Venter, et al., 2001). This non-coding
DNA contains introns, as well as genes that produce non-coding RNAs, including transfer RNA,
ribosomal RNA, small nuclear RNA, small nucleolar RNA, microRNAs, small interfering
mRNAs, and small temporal RNAs (Eddy, 2001) (Moss, 2001).
Non-coding DNA also contains numerous other functionally important sequences, including those
necessary for maintenance of chromosome ends, proper segregation of chromosomes during cell
division, and initiation and regulation of gene expression. Much of our genome has no currently
known function; this sequence includes pseudogenes, and the roughly 48% of our DNA that
consists of interspersed repetitive elements. This latter group includes many types of transposon-
derived repeats, as well as simple sequence repeats (Oetting, et al., 1996). Over 90% of genes
contain at least one and usually several alternative splice variants, in which the exons are combined
in different ways to produce 2 or more gene products from the same locus.
1.1. Genetic Variation
Variation, in biology is, any difference between cells, individual organisms, or groups of
organisms of any species caused either by genetic differences (genotypic variation) or by the effect
of environmental factors on the expression of the genetic potentials (phenotypic variation).
Variation may be shown in physical appearance, metabolism, fertility, mode of reproduction,
behavior, learning and mental ability, and other obvious or measurable characters.
Genotypic variations are caused by differences in number or structure of chromosomes or by
differences in the genes carried by the chromosomes. Eye color, body form, and disease resistance
are genotypic variations. Environmentally caused variations may result from one factor or the
combined effects of several factors, such as climate, food supply, and actions of other
organisms. Phenotypic variations also include stages in an organism’s life cycle and seasonal
variations in an individual. These variations do not involve any hereditary alteration and in general
are not transmitted to future generations; consequently, they are not significant in the process
of evolution (The Editors of Encyclopaedia Britannica, 2018).
Genetic variation results in different forms, or alleles, of genes. Any variation that occurs will be
due to the genes inherited from our parents. For example, eye color, skin tone and face shape are
3all determined by our genes. In contrast, although weight is partly influenced by our genetics, it is
strongly influenced by our environment. For example, how much we eat and how often we
exercise. Genetic variation can also explain some differences in disease susceptibility and how
people react to drugs (The Editors of yourgenome, 2015).
Nevertheless, most traits are more complex and are controlled by multiple interacting genes within
and among organisms (Phillips, 2008) (Wu & Lin, 2006). Genetic variation defines the difference
in DNA among individuals. It measures the variation that exists in the genetic makeup of
individuals within population. Genetic variation is caused by variation in the order of bases in
the nucleotides in genes (EMBL-EBI Training, 2017).
Genetic variation can be identified from observations of phenotypic variation in either quantitative
traits (e.g., height) or discrete traits (e.g., color). It can also be identified by examining variation
at the level of proteins using protein electrophoresis.
Nowadays, the new technologies allow scientists to directly sequence DNA. Analysis of DNA has
shown genetic variation in both coding regions and in the non-coding intron region of genes.
Phenotypic variation is the result of genetic variation in the nucleotides in the DNA
sequence which in turn results in a difference in the amino acids in proteins coded by that DNA
sequence, and if the consequential differences in amino acid sequence influences the shape, and
thus the function of the enzyme (Pavlopoulos, et al., 2013). For a given genome of a multicellular
organism, genetic variation may be acquired in somatic cells or inherited through the germline
cells.
There are numerous sources of genetic variation, including mutation, and genetic recombination
(crossing over between chromatids of homologous chromosomes during meiosis) (EMBL-EBI
Training, 2017). Random mutations are the ultimate source of genetic variation. Mutations are
likely to be rare and most of them are neutral or deleterious, but in some occasions, the new alleles
can be favored by natural selection. Genetic variation is important in evolution. Evolution relies
on genetic variation that is passed down from one generation to the next. Favorable characteristics
are ‘selected’ for, survive and are passed on. This is known as natural selection (The Editors of
yourgenome, 2015). Genetic variation is advantageous to a population because it enables some
individuals to adapt to the environment while maintaining the survival of the population (Lumen
Online Homework Manager, 2017). During meiotic cell division, crossing over (genetic
4recombination) and random segregation can result in the production of new alleles or new
combinations of alleles. Furthermore, random fertilization and random mating between organisms
also contributes to variation (Lumen Online Homework Manager, 2017) (Pavlopoulos, et al.,
2013).
The Human Genome Project (HGP) was an international scientific research project with the goal
of determining the sequence of nucleotide base pairs that make up human DNA, and of identifying
and mapping all of the genes of the human genome from both a physical and a functional
standpoint (WGBH, 2003). The project formally launched in 1990 and was declared complete on
April 14, 2003 (National Human Genome Research Institute, 2018). Funding came from the US
government through the National Institutes of Health (NIH) as well as numerous other groups from
around the world. Most of the government-sponsored sequencing was performed in twenty
universities and research centers in the United States, the United Kingdom, Japan, France,
Germany and China (National Human Genome Research Institute, 2018).
The Human Genome Project (HGP) was declared complete in April 2003. An initial rough draft
of the human genome was available in June 2000 and by February 2001 a working draft had been
completed and published followed by the final sequencing mapping of the human genome on April
14, 2003. Although this was reported to cover 99% of the euchromatic human genome with 99.99%
accuracy, a major quality assessment of the human genome sequence was published on May 27,
2004 indicating over 92% of sampling exceeded 99.99% accuracy which was within the intended
goal. (Schmutz, et al., 2004) Further analyses and papers on the HGP continue to occur (U.S.
Department of Energy, 2019). There are approximately 22,300 protein-coding genes in human
beings, the same range as in other mammals (Mihaela & Steven, 2010).
The sequence of the DNA is stored in databases available to anyone on the Internet. The
U.S. National Center for Biotechnology Information (and sister organizations in Europe and
Japan) house the gene sequence in a database known as GenBank, along with sequences of known
and hypothetical genes and proteins. Other organizations, such as the UCSC Genome Browser at
the University of California, Santa Cruz, (Bentley, 2000) and Ensemble (James, et al., 2004)
present additional data and annotation and powerful tools for visualizing and searching it.
In 2002 the National Institutes of Health started a $138 million project called the HapMap to
catalog the common variants in European, East Asian and African genomes) (Naidoo, et al., 2011).
Although the main sequencing phase of the HGP has been completed, studies of DNA variation
5continued in the International HapMap Project, whose goal was to identify patterns of single-
nucleotide polymorphism (SNP) groups (called haplotypes, or “haps”). The genome published by
the HGP does not represent the sequence of every individual's genome. It is the combined mosaic
of a small number of anonymous donors, all European origin. The HGP genome is a scaffold for
future work in identifying differences among individuals. Subsequent projects sequenced the
genomes of multiple distinct ethnic groups, though as of today there is still only one "reference
genome”.
1.2. Pharmacogenetics
Pharmacogenetics, related to pharmacology, is the study of genetic factors influencing drug
response. In broad terms, it’s the study of the genetic variation between individuals that affects
their response to drugs/pharmaceuticals and other xenobiotics, both therapeutically and in terms
of adverse effects (side effects). Personalized medicine is the use of pharmacogenetics to
understand how an individual can benefit from specific drugs (Springer Nature , 2019 ). It analyzes
how the genetic makeup of an individual affects his/her response to drugs (Gennady, 2015), and it
deals with the influence of acquired and inherited genetic variation on drug response in patients
by correlating gene expression or single-nucleotide polymorphisms (SNPs) with pharmacokinetics
(drug absorption, distribution, metabolism, and elimination) and pharmacodynamics (effects
mediated through a drug's biological targets) (UNC: Eshelman School of Pharmacy, 2014) (Julie,
2003) (Kelan & Scott, 2014).
The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both
terms relate to drug response based on genetic influences, pharmacogenetics is the study of
interindividual variations in DNA sequence related to drug response, while pharmacogenomics is
the study of the variability of the expression of individual genes relevant to disease susceptibility
as well as drug response at cellular, tissue, individual or population level (European Medicines
Agency, 2002).
Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the
patients' genotype, to ensure maximum efficiency with minimal adverse effects (Becquemont,
2009). Pharmacogenomics also attempts to eliminate the trial-and-error method of prescribing,
allowing physicians to take into consideration their patient's genes, the functionality of these genes,
and how this may affect the efficacy of the patient's current or future treatments (and where
applicable, provide an explanation for the failure of past treatments) (Sheffield & Phillimore, 2009)
6(Hauser, et al., 2018). Such approaches promise the advent of precision medicine and
even personalized medicine, in which drugs and drug combinations are optimized for narrow
subsets of patients or even for each individual's unique genetic makeup (U.S. Food and Drug
Administration, 2005) (Squassina, et al., 2010). Whether used to explain a patient's response or
lack thereof to a treatment, or act as a predictive tool, it hopes to achieve better treatment outcomes,
greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions
(ADRs).
Usually patient genotypes are categorized into four predicted phenotypes:
 Ultra-rapid metabolizer: patients with substantially increased metabolic activity
 Extensive metabolizer: normal metabolic activity
 Intermediate metabolizer: patients with reduced metabolic activity
 Poor metabolizer: patients with little to no functional metabolic activity
The two extremes of this spectrum are the poor metabolizers and ultra-rapid metabolizers. Efficacy
of a medication is not only based on the above metabolic statuses, but also the type of drug
consumed. Drugs can be classified into two main groups: active drugs and prodrugs. Active drugs
refer to drugs that are inactivated during metabolism, and prodrugs are inactive until they are
metabolized (Cohen, 2008).
Some of the commonly known applications of pharmacogenomics include: Improve drug safety
and reduce ADRs; Tailor treatments to meet patients' unique genetic pre-disposition, identifying
optimal dosing; Improve drug discovery targeted to human disease; and Improve proof of principle
for efficacy trials (Cohen, 2008).
1.3. Genetic Polymorphism
Polymorphism is a combination of the Greek words poly- (meaning multiple) and morph-
(meaning form), polymorphism is a term used in genetics to describe multiple forms of a single
gene that exists in an individual or among a group of individuals (Phillips T. , 2019). Where
monomorphism means having only one form and dimorphism means there are only two forms, in
genetics and biology, the term polymorphism is a very specific term, relating to the multiple forms
of a gene that can exist. The term does not extend to heritable character traits with a continuous
variation such as height. Instead, polymorphism refers to forms that are discontinuous (have
7discrete variation), bimodal (having or involving two modes), or polymodal (multiple modes). For
example, earlobes are either attached, or they are not, it is an either/or situation and not like height,
which is not a set number or another (Phillips T. , 2019).
1.4. Single Nucleotide Polymorphisms (SNPs)
A gene is said to be polymorphic if more than one allele occupies that gene’s locus within a
population. In addition to having more than one allele at a specific locus, each allele must also
occur in the population at a rate of at least 1% to generally be considered polymorphic (Biology
Online Dictionary, 2019) (Ford, Ecological Genetics , 1975).
Put simply, polymorphism is when there are two or more possibilities of a trait on a gene. The
most common type of genetic variation amongst people is the single nucleotide polymorphisms
(SNPs, pronounced ‘snips’). Each single nucleotide polymorphism represents a difference in a
single DNA base, adenine (A), guanine (G), thymine (T), or cytosine (C), in a person’s DNA
molecule. On average they occur once in every 300 bases and are often found in the DNA between
genes (Ford, Polymorphism and Taxonomy , 1940) (National Human Genome Research Institute,
2017).
Gene polymorphisms can occur in any region of the genome. In fact, roughly 90% of the genetic
variation that exists between humans is the result of SNPs, although most polymorphisms are
silent, do not alter cellular function and thus have no effect. Some polymorphisms have a
detectable impact on function and have been discovered to contribute to the development of
diseases such as cancer and to influence physiological responses to drugs (Chanock, 2007).
A polymorphic variant of a gene can lead to the abnormal expression or to the production of an
abnormal form of the protein; this abnormality may cause or be associated with disease. For
example, a polymorphic variant of the enzyme CYP4A11 in which thymidine replaces cytosine at
the gene's nucleotide 8590 position encodes a CYP4A11 protein that substitutes phenylalanine
with serine at the protein's amino acid position 434. This variant protein has reduced enzyme
activity in metabolizing arachidonic acid to the blood pressure-regulating eicosanoid, 20-
hydroxyeicosatetraenoic acid. A study has shown that humans bearing this variant in one or both
of their CYP4A11 genes have an increased incidence of hypertension, ischemic stroke,
and coronary artery disease (Wu, et al., 2014).
8SNPs act as chromosomal tags to specific regions of DNA, and these regions can be scanned for
variations that may be involved in a human disease or disorder. SNPs found to be associated with
disease may be useful for diagnostic purposes. In addition, identifying which variations are
involved in altering responses to drugs could facilitate the development of personalized medicine.
This approach to treatment is based on the concept that genetic screening for specific SNPs in a
person’s genome can be used to select drugs or adjust dosages most appropriate for that individual.
Personalized medicine could be used to avoid potentially dangerous drug responses that are the
result of altered cellular metabolism caused by a specific SNP (The Editors of Encyclopaedia
Britannica, 2019).
A mutation may create a polymorphism in the population if the resulting variant form is transmitted
to subsequent generations without causing major defects in biological functions.
Mutations originate from unrepaired DNA damage caused by replication errors and lesions from
endogenous or exogenous mutagens as well as from insertion or deletion of DNA segments of
DNA by mobile elements. Mutant proteins or nucleic acids that causes inherited diseases are
considered mutations rather than polymorphisms even though they may exist in the population at
significant levels – e.g. higher than the 1% level noted.
Polymorphism is related to population diversity. Mutation can be germ line or somatic. Germline
mutation is the cause of polymorphism in sexual reproductive population of a species.
All polymorphisms result from mutations but not all mutations will go on to become
polymorphisms. A mutation (in DNA) is a change in DNA sequence away from the "reference",
not the "normal", because in real biological populations or in the wild, there is really no "normal"
or "wild-type", only varying frequencies of different alleles, i.e. polymorphism due to natural
variation. Mutations by themselves do not classify as polymorphisms. A polymorphism is a DNA
sequence variation that is common in the population. A mutation, on the other hand, is any change
in a DNA sequence away from normal (implying that there is a normal allele running through the
population and that the mutation changes this normal allele to a rare and abnormal variant)
Polymorphism is common in nature; it is related to biodiversity, genetic variation, and adaptation.
Continued research into gene-environment interactions may lead to more specialized treatment
plans based on an individual's surroundings (Theresa, 2019) (Ford, Ecological Genetics , 1975)
(Ford, Polymorphism and Taxonomy , 1940) (Sheppard, 1975).
9Common polymorphisms include tandem repeated segments, large (copy number variants) and
small segmental deletions/insertions/duplications, and substitutions (SNPs). SNPs are an
exceedingly common form of polymorphism that may account for approximately 90% of all
known sequence variation (Kerb, 2006) (Collins, et al., 1998). Functional SNPs that lead to
changes in gene expression occur in all regions of the genome. SNPs in the coding (exonic) regions
of transporter genes can be nonsynonymous, meaning that they lead to a change in encoded amino
acids, or synonymous (no amino acid change). Although both kinds of SNPs can have an impact
on transporter activity, it is widely accepted that nonsynonymous SNPs are more likely to have
functional consequences. Nonsynonymous SNPs can lead to protein misfolding, polarity shift or
improper phosphorylation. SNPs in the noncoding regions of transporter genes are less predictable
and include variants in the intronic, promoter and 3’-untranslated region (3’UTR). These variants
can affect the splicing or regulation of transporter genes. SNPs in the promoter region may modify
transporter expression by altering the binding sites for transcription factors (Chorley, et al., 2008)
(Gradhand & Kim, 2008).
Polymorphism in drug transporters plays a major role in interindividual differences in drug
disposition. Polymorphism leading to functional changes in drug transporters can affect the
pharmacokinetics and subsequent pharmacodynamics and toxicological effects of drugs. It can
also affect susceptibility to certain diseases (Ho & Kim, 2005). Although detailed information on
genetic variability in drug transporter genes is available, our knowledge on identifying those
genetic variants that have functional significance and how they contribute to interindividual
variability in drug response is still limited.
Polymorphisms in transporter genes can have profound effects on statin pharmacokinetics. A
common genetic variant of organic anion-transporting polypeptide 1B1 (OATP 1B1) reduces the
hepatic uptake of many statins, increasing the risk of statin-induced myopathy. Similarly,
genetically impaired adenosine triphosphate (ATP)-binding cassette G2 (ABC G2) transporter
efflux activity, results in a marked increase in systemic exposure to various statins. Importantly,
the effects of these genetic polymorphisms differ depending on the specific statin that is used. This
provides a rational basis for the individualization of lipid-lowering therapy (Niemi, 2010).
1.5. Membrane Transporters
In addition to the physicochemical properties of a compound such as charge, molecular size,
lipophilicity and solubility, carrier-mediated processes or transporters also affect the
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transmembrane passage of substrates. Transporters are usually separated into two major classes -
uptake and efflux transporters (Figure 1.1); it has been estimated that approximately 2000 genes
encode transport proteins in humans (Giacomini & Sugiyama, 2006). The polarized expression of
transporters in targeted organs such as the intestine, kidney and liver and the dynamic interplay
between uptake and efflux transporters, often with overlapping substrate capabilities, in the cell
membrane of epithelial cells, together determine the direction and extent of flow of a number of
xenobiotic and endobiotic substances (Kerb, 2006). Moreover, their expression on the interfaces
of different parts of the body contributes to the maintenance of several important structural
barriers, e.g. the blood-brain barrier and the blood-placental barrier (Graff & Pollack, 2004)
(Syme, et al., 2004) (Molsa, et al., 2005). Transporters mediate important physiologic functions
via influx and efflux of endogenous substrates such as amino acids, bile acids, steroids, sugars,
lipids and hormones that are critical for normal homeostasis. They also play a significant role in
mediating the absorption, tissue distribution and elimination of many environmental toxins and
drugs (Ho & Kim, 2005) (Shitara & Sugiyama, 2006).
Figure 1.1. Different modes of transport mediated by the solute carriers (SLCs), ATP-binding
cassette (ABC) transporters and channels in the plasma membrane (Petzinger & Geyer, 2006)
Influx (uptake) transporters facilitate the entry of drugs into cells. Uptake transporters include the
organic anion-transporting polypeptides (OATPs, SLCO), organic anion transporters (OATs,
Concentration Gradient
/Membrane Potential SLC Carriers ABC Carriers
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SLC22A), organic cation transporters (OCTs, SLC22A), organic cation/carnitine transporters
(OCTNs, SLC22A), peptide transporters (PEPTs, SLC15A) and sodium-dependent taurocholate co-
transporting protein (NTCP, SLC10A1) (Ho & Kim, 2005) (Zair, 2008). Multidrug and toxin
extrusion transporter 1 (MATE1, SLC47A1) and multidrug and toxin extrusion transporter 2-K
(MATE2-K, SLC47A2) also participate into the uptake of compounds into the cell. All these
transporters belong to the superfamily of solute carriers (SLCs) (Hagenbuch & Meier, 2004)
(Hediger, et al., 2004) (Seithel, et al., 2008a).
1.6. Role of Transporters in Drug Disposition
In the gut, drug absorption from the intestinal lumen is facilitated by uptake transporters and
limited by efflux transporters, both expressed in the brush-border membrane of enterocytes (Figure
1.2). Following uptake, drugs are translocated via the basolateral membrane into the portal blood
circulation by efflux transporters such as the multidrug resistance-associated proteins (MRPs).
Many drugs also pass through the enterocytes by passive diffusion and some drugs already undergo
extensive metabolism in the enterocytes (Kullak-Ublick, et al., 2004) (Glaeser, et al., 2007) (Meier,
et al., 2007).
Uptake transporters like organic anion transporting polypeptide 1B1 (OATP 1B1) expressed on
the basolateral (sinusoidal) membrane of hepatocytes facilitate the influx of compounds into the
liver from the portal blood (Figure 1.2). Drugs taken into the hepatocytes often undergo metabolic
transformation and/or conjugation, or they may be excreted unchanged (Pang & Rowland, 1977).
Transport of the drugs and their metabolites out of the hepatocyte via the canalicular membrane
into the bile or via the basolateral membrane back into the portal blood may be mediated by efflux
transporters (Shitara & Sugiyama, 2006).
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Figure 1.2. Drug elimination in the liver involves uptake into hepatocytes via transporters and/or
passive diffusion, followed by metabolism and efflux to the bile or blood (Pasanen M. , 2008).
1.7. Pharmacogenomics of Statins
Statins are reversible competitive inhibitors of the HMG-CoA reductase enzyme, which catalyzes
the first and rate-limiting step from HMG-CoA to mevalonate in de novo cholesterol synthesis.
Figure 1.3 depicts the biosynthetic pathway of cholesterol and other cometabolites.
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Figure 1.3. Simplified scheme of the biosynthetic pathway of cholesterol and other cometabolites
(Turner & Pirmohamed, 2018)
The pharmacogenomics of statins involves many different genes, including those involved in the
pharmacokinetics (PK) effects of the drug transport and metabolism (Figure 1.4) and those
involved in mediating the pharmacodynamic (PD) effects of statins on plasma lipoprotein
metabolism (Whirl-Carrillo, et al., 2012) (Figure 1.5).
Statins (atorvastatin, lovastatin and simvastatin, fluvastatin, pravastatin and rosuvastatin) are
dosed orally and enter the systemic circulation through intestinal cells both passively and by active
transport via the ABC and SLC gene family transporters (Figure 1.4). The major organs of
metabolism and elimination include the liver and, to a lesser extent, the kidney. Metabolism is
catalyzed by CYP and UGT gene family enzymes. The main pathway of elimination is ABC
transporter mediated biliary excretion (Whirl-Carrillo, et al., 2012).
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Figure 1.4. Representation of the superset of all genes involved in the transport, metabolism and
clearance of statin class drugs (Whirl-Carrillo, et al., 2012)..
Inhibition of HMG CoA reductase reduces cholesterol synthesis in the hepatocytes, leading to a
reduction in intracellular cholesterol concentration and a responsive increase in LDL receptor
expression on the hepatocyte cell surface. This results in increased extraction of LDL-C from the
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blood and decreased circulating total cholesterol and LDL-C concentrations. A meta-analysis
showed that statins can lower LDL-C by an average of 1.8 mmol/l, which reduces the risk of CHD
events by about 60% and stroke by 17% (Seithel, et al., 2007).
In addition to lowering plasma LDL-C and total cholesterol levels, statins also moderately reduce
triglyceride levels and increase HDL-cholesterol levels (Kreisberg & Oberman, 2002). Secondary
mechanisms by which statins may reduce lipoprotein levels include inhibition of hepatic synthesis
of apoB100 and reduction in synthesis and secretion of triglyceride-rich lipoproteins (VLDL and
IDL). In addition, the inhibition of synthesis of nonsteroidal isoprenoid compounds (also produced
from mevalonate) (Figure 1.5) may explain the pleiotropic properties of statins leading to
beneficial cardiovascular effects independent of their lipid-modifying properties. These include
restoration of endothelial cell function, modification of inflammatory responses, antithrombotic
and antioxidant effects, as well as reduction of smooth muscle cell proliferation and cholesterol
accumulation. These biological effects beyond LDL reduction may differ among statins (Rosenson
& Tangney, 1998) (Chong, et al., 2001) (Bonetti, et al., 2003). Statins have been shown to slow
the progression or even promote regression of coronary atherosclerosis, possibly due to shrinkage
of the lipid core of the atherosclerotic plaque, avoiding plaque rupture that would otherwise trigger
intramural hemorrhage and intraluminal thrombosis (Kreisberg & Oberman, 2002) (Liao, 2002).
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Figure 1.5. Genes involved in mediating statin effects on hepatic cholesterol metabolism and
consequent effects on plasma lipoprotein transport (Whirl-Carrillo, et al., 2012).
Interindividual variation in the response to statins limits the beneficial effects of statin therapy.
Genetic differences in drug metabolizing enzymes or drug transporters can also predispose to statin
myotoxicity. A study analyzed two sets of patient and control groups from large trials involving
approximately 12 000 and 20 000 participants, treated with 80 mg and 40 mg of simvastatin per
day, respectively (Pasanen M. , 2008). A strong association was found between myopathy and two
tightly linked variants in the influx transporter gene SLCO1B1, one of them being the c.521T>C
variant. The odds ratio for myopathy was 4.5 per copy of the c.521C allele, and 16.9 in c.521CC,
compared with the c.521TT homozygotes. In this large-scale study, approximately 60% of the
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simvastatin-induced myopathy cases were attributable to the c.521 variant allele. In a previous
Japanese study, the SLCO1B1*15 haplotype also containing the c.521T>C SNP (c.388G-c.521G)
was associated with pravastatin-induced myopathy (Morimoto, et al., 2004) (Morimoto, et al.,
2005).
1.8. Organic Anion Transporting Polypeptides (OATPs)
Organic anion transporting polypeptides (OATPs (rodents: Oatps; human: OATPs)) are basolateral
plasma membrane transport proteins that mediate the sodium-independent uptake of amphipathic
compounds including bile salts, steroid conjugates, thyroid hormones, anionic oligopeptides and
conjugated and unconjugated bilirubin (Hagenbuch & Meier, 2004).
Their transport mechanism is electroneutral exchange, coupling the cellular uptake of organic
compounds with the efflux of neutralizing anions such as bicarbonate, glutathione or glutathione-
S-conjugates (Satlin, et al., 1997) (Li, et al., 1998). OATPs have been identified at least in the
intestine, liver, kidney, lung, testis, placenta and blood-brain barrier. Genes encoding the OATP
uptake transporters form a large family of solute carrier organic anion transporters (SLCO) within
the SLC superfamily (Hagenbuch & Meier, 2004). OATPs in the OATP/SLCO superfamily are
subdivided into families indicated by a number for > 40% amino acid sequence identity (e.g.
OATP1/SLCO1), into subfamilies indicated by a letter for >60% amino acid sequence identity
(e.g. OATP1B /SLCO1B) and into individual genes and gene products indicated by an additional
number (e.g. OATP1B1/SLCO1B1), according to the phylogenetic relationships and chronology
of identification (Hagenbuch & Meier, 2004). OATP1A2 (previously known as OATP-A) was the
first member to be described, followed by the discovery of OATP1B1 in 1999 (Kullak-Ublick, et
al., 1995) (Abe, et al., 1999) (Hsiang, et al., 1999) (Konig, et al., 2000). Up to now, 36 mammalian
OATPs and 11 human OATPs have been identified (Hagenbuch & Meier, 2003) (Mikkaichi, et
al., 2004). OATP1B1, encoded by the gene SLCO1B1, is one of the main sodium-independent bile
acid and organic anion transporters in the liver (Hsiang, et al., 1999) (Konig, et al., 2000).
In a recent study, OATP1B1 was also found at the messenger ribonucleic acid (mRNA) level in
small intestinal enterocytes (Glaeser, et al., 2007). In addition to the physiological function,
OATPs have been found to transport an increasing number of frequently used drugs, such as
several HMG CoA reductase inhibitors (statins), fexofenadine, benzylpenicillin, repaglinide,
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valsartan, and temocaprilat (Maeda, et al., 2006). OATPs can be inhibited by cyclosporine,
rifampicin, gemfibrozil and macrolides (Niemi, 2007).
OATP1B1 (previously known as OATP-C, OATP2, SLC21A6, and liver specific transporter 1
LST-1) is one of the most important influx transporter proteins in the OATP family of transporters
(Hagenbuch & Meier, 2004). OATP1B1 is expressed in the sinusoidal membrane of hepatocytes
and participate in the active uptake of compounds from the portal blood into the liver (Hagenbuch
& Meier, 2004) (Niemi, 2007).
Numerous genetic polymorphisms have been identified in the OATP1B1encoding gene. Indeed,
polymorphisms in SLCO1B1 has recently been associated with altered pharmacokinetics of
pravastatin, pitavastatin, simvastatin, atorvastatin, rosuvastatin, repaglinide, nateglinide,
fexofenadine, atrasentan, paclitaxel, digoxin and also with variable changes in cholesterol levels
following statin administration (Hedman, et al., 2006) (Pasanen, et al., 2006) (Niemi, et al., 2005)
(Maeda, et al., 2006)
1.8.1. Structure and Function
Bioinformatics analysis using various topology models has revealed that OATP1B1 is a 691-amino
acid glycoprotein with 12 putative membrane-spanning domains (currently accepted structure
based on hydropathy analyses) and a large fifth extracellular loop (Pasanen, et al., 2006) (Chang,
et al., 2005) (Figure 1.6). Common to all OATP proteins, OATP1B1 carries N-glycosylation sites
in extracellular loops 2 and 5. It has two potential phosphorylation sites and transmembrane
domain 10 (TM10) is critical for its function. Its apparent molecular mass is 84 kDa, which is
reduced after deglycosylation to 54 kDa (Konig, et al., 2000). It’s almost exclusive expression in
the human liver suggests that it plays a crucial role in the hepatic uptake and clearance of
amphipathic organic compounds.
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Figure 1.6. The predicted transmembrane secondary structure of OATP1B1, depicting the
positions of nonsynonymous single nucleotide polymorphisms (Mikko, et al., 2011).
The mechanism or driving force for transport of substrate transport is not completely understood,
although it has been suggested that OATPs translocate their substrates through a central, positively
charged pore in a so-called rocker-switch type of mechanism (Meier-Abt, et al., 2005). However,
a report demonstrated that the transporter is influenced in different ways by both pH and the
membrane potential (Martinez-Becerra, et al., 2011). This transport is independent of sodium,
chloride and potassium gradients, membrane potential and ATP levels. The phosphorylation state
of at least the rat Oatp1a1 is important for transport, since extracellular ATP reduces Oatp1a1-
mediated bromosulphophtalein (BSP) transport in rat hepatocytes via phosphorylation of
intracellular serine residues (Glavy, et al., 2000). No higher solution structures are currently known
for OATP1B1, but one recent study using three-dimensional quantitative structure-activity
relationship models showed that OATP1B1 substrates produce a pharmacophore containing two
hydrogen bond acceptors, one hydrogen bond donor and two hydrophobic regions (Hagenbuch &
Meier, 2004). In another study using a meta-pharmacophore approach combining limited datasets
from different laboratories, cell types and species, a meta-model for OATP1B1was generated in
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which the hydrophobic features are centrally located, and hydrogen bond features located at the
extremities (Chang, et al., 2005).
1.8.2. Substrates
In general, OATP substrates appear to be anionic amphipathic molecules with a rather high
molecular weight (> 450) and a high degree of albumin binding under physiological conditions
(Hagenbuch & Meier, 2004). A variety of endogenous compounds such as bile acids, steroid
conjugates, bilirubin glucuronides, thyroid hormones, eicosanoids, cyclic peptides and BSP are
substrates of OATP1B1. Substrate drugs include the ACE inhibitors enalapril and temocapril, the
angiotensin II receptor antagonists olmesartan and valsartan, the antifungal agent caspofungin, the
antibiotics rifampicin and benzylpenicillin, methotrexate, the endothelin receptor antagonists
atrasentan and bosentan, troglitazone sulphate, the active SN-38 metabolite of the anticancer agent
irinotecan, fexofenadine, the glucuronide of the cholesterol-lowering drug ezetimibe and the
statins atorvastatin, cerivastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin
acid. The pharmacokinetics of repaglinide has been associated with OATP1B1 transport function;
although there is no in vitro evidence showing that it is an OATP1B1 substrate (Niemi, et al.,
2005a) (Kalliokoski, et al., 2008b). In addition, the natural toxins microcystin and phalloidin are
substrates of OATP1B1 (Hagenbuch & Meier, 2003). Reports on unbound bilirubin being a
substrate of OATP1B1 are somewhat controversial, since it has been shown to be transported by
this transporter in both HEK293 (human embryonic kidney) cells and Xenopus laevis oocytes, but
no transport was observed in another study with HeLa (human cervical carcinoma) and HEK293
cells (Cui, et al., 2001) (Briz, et al., 2003) (Wang, et al., 2003).
1.8.3. Inhibitors
It is widely agreed that inhibition of OATP1B1-mediated hepatic uptake of substrate drugs
contributes to these clinically observed drug interactions (Shitara, et al., 2003). Gemfibrozil and
its glucuronide metabolite also inhibit OATP1B1 and significantly increase the plasma
concentrations of several OATP1B1 substrate drugs including simvastatin acid (Backman, et al.,
2000), lovastatin acid and pravastatin (Kyrklund, et al., 2003) (Kyrklund, et al., 2001), cerivastatin
(Backman, et al., 2002), repaglinide (Niemi, et al., 2003b), rosuvastatin (Schneck, et al., 2004) and
atorvastatin (Backman, et al., 2005). Rifampicin, a strong inducer of drug-metabolizing enzymes,
has increased the expression of OATP1B1 in cultured human hepatocytes in vitro (Niemi, et al.,
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2003a) (Jigorel, et al., 2006). This may explain the slight decrease in plasma pravastatin
concentrations when administered concomitantly with rifampicin (Kyrklund, et al., 2004). On the
other hand, rifampicin is a relatively potent inhibitor of OATP1B1 and OATP1B3 in vitro
(Vavricka, et al., 2002) In addition, the antimicrobial drugs clarithromycin, erythromycin,
roxithromycin and telithromycin as well as the HIV protease inhibitors indinavir, ritonavir and
saquinavir have been identified as OATP1B1 inhibitors in vitro (Campbell, et al., 2004) (Hirano,
et al., 2006) (Seithel, et al., 2007).
1.9. Pharmacogenetics of SLCO1B1
The organic anion transporting polypeptide 1B1 (OATP1B1) is a genetically polymorphic influx
transporter expressed on the sinusoidal membrane of human hepatocytes, and it mediates the
hepatic uptake of many endogenous compounds and xenobiotics. Studies have demonstrated that
OATP1B1 plays a major, clinically important role in the hepatic uptake of many drugs.
The SLCO1B1 gene is located in chromosome 12 (gene locus 12p12). Many SNPs, both
nonsynonymous and synonymous, have been discovered in the SLCO1B1 gene, and several of
these affect transport function in vitro and in vivo. Most of the SNPs associated with altered
transport function span the transmembrane domains or extracellular loop 5 of OATP1B1. The
effects of certain SLCO1B1 polymorphisms on transport function appear to be substrate dependent
(Tirona et al., 2001).
Cytogenetic location 12p12.2
Physical location 21.284.127 - 21.392.728
Exons 15
bp 2800
AA 691
Category Transport carrier
Superfamily/Family solute carriers (SLC21A)/ OATP
Conserved AAs R57, K361 and R580
Subcellular localization Basolateral membrane of hepatocytes
Physiological process Active transport
Regulated by HNF1A
Transmembrane domains (helices) 12
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HGNC id 10959
Haplotypes SLCO1B1(*1A, *1B, *5 and *15)
Common variants 190
Table 1.1. Description of the SLCO1B1 gene (Whirl-Carrillo, et al., 2012) (NCBI, 2016)
The pharmacogenetics of solute carrier organic anion transporter family member 1B1 (SLCO1B)
has been the topic of several studies. Two common nonsynonymous SLCO1B1variants have been
well characterized: rs2306283 (SLCO1B1: 492A>G on NM_0064464, previously referred to as
388A>G; encoding OATP1B1:N130D) and rs4149056 (SLCO1B1 625T>C on NM_006446.4;
commonly referred to as T521C, encoding OATP1B1:V174A). These two variants are in partial
linkage disequilibrium. Consequently, there are four important haplotypes with these
variants: SLCO1B1*1A, containing neither variant, SLCO1B1*1B (rs2306238), SLCO1B1*5
(rs4149056) and SLCO1B1*15 (with both variants) (Oshiro, et al., 2010 ) (Turner & Pirmohamed,
2014). SLCO1B1 single nucleotide polymorphisms and haplotypes have been implicated in altered
pharmacokinetic handling and pharmacodynamic response for several major drug classes. In
cellular studies, OATP1B1-Ala174 and associated haplotypes, particularly SLCO1B1*15, have
shown reduced transport activity in comparison with OATP1B1-Val174. This may be a result of
intracellular protein sequestration and reduced surface expression (Rommel, et al., 2001)
(Kameyama, et al., 2005).
The rs4149056 SNP (DNA c.521T>C, protein p.V174A) in the SLCO1B1 gene encoding
OATP1B1 decreases the transporting activity of OATP1B1, resulting in markedly increased
plasma concentrations of, for example, many statins, particularly of active simvastatin acid. The
variant thereby enhances the risk of statin-induced myopathy and decreases the therapeutic indexes
of statins. Consequently, the importance of SLCO1B1 genetic variants in clinical
pharmacogenetics is underlined by the fact that the US Food and Drug Administration
recommendations for some drugs (e.g. simvastatin) have already incorporated information
regarding pharmacogenetic information about SLCO1B1 in their drug label (www.fda.gov).
Extensive literature and FDA warning labels indicate increased risk for myopathy in patients with
specific genetic differences on the SLCO1B1 gene. Guidelines regarding the use of
pharmacogenomic tests in dosing for simvastatin have been published in Clinical Pharmacology
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and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) (Wilke,
et al., 2012).
However, the SLCO1B1 c.521T>C variant can have a different effect on different statins. The same
variant also distinctly affects the pharmacokinetics of several other drugs. For example, an
enhanced clearance of methotrexate, which increases the risk of gastrointestinal toxicity in the
treatment of children with acute lymphoblastic leukemia is associated with certain SLCO1B1
variants. some drugs (e.g., cyclosporine) potently inhibit OATP1B1, causing clinically significant
drug interactions. Thus, OATP1B1 plays a major role in the hepatic uptake of drugs, and genetic
variants and drug interactions affecting OATP1B1 activity are important determinants of
individual drug responses (Niemi, et al, 2011).
One of the most characterized SNPs in SLCO1B1, the c.521T>C SNP, predicts the substitution of
alanine for valine at amino acid 174 (Val174Ala). Another prevalent SNP, c.388A>G, causes an
amino acid change at position 130 (Asn130Asp). When the effects of SNPs on the respective
phenotype are assessed, the underlying haplotype structure should be taken into account. The
c.388A>G and the c.521T>C variants are in linkage disequilibrium (LD) and exist in variable
SLCO1B1 haplotypes together. The c.388A-c.521T haplotype is known as *1A (reference
haplotype), c.388G-c.521T as *1B, c.388A-c.521C as *5 and c.388G-c.521C as *15. Moreover, at
least in Europeans, the haplotypes comprising c.388A>G and c.521T>C can be further
subclassified by two promoter region SNPs g.-11187G>A and g.-10499A>C into two other
distinctive and potentially functional significant haplotypes: *16 and *17 (Figure 7) (Niemi, et al.,
2004). The c.521C allele and the haplotypes *5 and *15 (containing the c.521T>C SNP) have been
associated with markedly reduced uptake activity in vitro of the OATP1B1 substrates oestrone 3-
sulphate, oestradiol-17-D-glucuronide, atorvastatin, cerivastatin, pravastatin, the SN-38
metabolite of irinotecan and rifampicin (Tirona, et al, 2001) (Tirona, et al, 2003) (Iwai, et al, 2004)
(Kameyama, et al., 2005)(Nozawa, et al., 2005).
As mentioned previously, OATP1B1-dependent transport is an important step in mediating hepatic
clearance of statins. The minor allele of SLCO1B1 T521C (present in *5, *15, *16, *17 haplotypes)
has been consistently associated with elevated circulating concentrations of statins, as measured
by plasma area under the curve (AUC) values or Cmax implying reduced hepatic access. Because
statins act primarily through hepatic mechanisms, reduced hepatic statin availability associated
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with SLCO1B1 T521C may also influence statin efficacy (Kivistö & Niemi, 2007) (Yohei, et al.,
2003) (Pasanen, et al., 2007).
OATP-C (-11187G>A) is another SNP in the promoter region of the gene. The c.521T>C variant
is generally referred to as a low-activity variant because it has been associated with markedly
reduced uptake activity of OATP1B1 substrates in vitro and markedly increased plasma
concentrations and reduced oral clearances in vivo compared with the *1A (reference) haplotype
in a variety of studies (Pasanen M. , 2008). However, it was unclear what the frequency was of
*15 compared with the *5 haplotype in other populations. In addition, the frequencies of other,
potentially functional, SNPs had been poorly elucidated in any population (Pasanen M. , 2008).
Figure 1.7. Schematic representation of functionally distinctive SLCO1B1 haplotypes (Pasanen M.
, 2008).
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1.10. Global Prevalence of The SNP (c.521T>C)
Regarding the high clinical importance of SLCO1B1 pharmacogene in drug dosing of statins, it is
noteworthy to evaluate the SLCO1B1 genotype not only of single patients, but also, the general
frequency of the polymorphisms in the whole populations of different ethnic backgrounds. Studies
showed that the global prevalence of the SLCO1B1 polymorphism (c.521T>C) is significantly
large and that considerable differences are observed in the prevalence of polymorphisms in
SLCO1B1 among populations from different ethnic origins (Mwinyi, et al., 2008) (Jada, et al.,
2007) (Table 1.2).
Ethnic group n c.521C allele (%) Reference
Finnish Caucasian 468 20 (Pasanen, et al, 2006)
Caucasian (European) 151 18 (Pasanen, et al, 2008)
German Caucasian 300 15 Mwinyi et al. 2008
Caucasian (Singapore) 36 22 Lee et al. 2005a
Native American 64 24 (Pasanen, et al, 2008)
European American 49 14 Tirona et al. 2001
African American 22 2.3 irona et al. 2001
Sub-Saharan African 105 1.9 (Pasanen, et al, 2008)
North African (Algerian) 29 17 (Pasanen, et al, 2008)
African (Ugandan) 115 3.9 Mwinyi et al. 2008
Japanese 27 19 (Oshiro, et al, 2010 )
Korean 22 25 Chung et al. 2005
Chinese 100 13 Jada et al. 2007
Malay 35 13 Lee et al. 2005a
Asian-Indian 35 7.1 Lee et al. 2005a
Indian 100 6.5 Jada et al. 2007
Turkish 94 12 Mwinyi et al. 2008
Pakistani 192 9.4 (Pasanen, et al, 2008)
Israeli 133 20 (Pasanen, et al, 2008)
Oceanian 28 0.0 (Pasanen, et al, 2008)
Table 1.2. Allelic frequencies (%) of SLCO1B1 variant in different populations.
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The studies show that large differences in allele frequencies exist between different populations
globally. The highest frequencies of the variant c.521C allele were found in America (24%; 95%
CI, 18–32%), Middle East (20%; 95% CI, 15–25%) and Europe (18%; 95% CI, 14–23%); the
smallest frequency was found in Sub-Saharan Africa (1.9%; 95% CI, 0.7–4.8%). The frequency
of c.521C was 12% (95% CI, 9.5–15%) in East Asia and 9.4% (95% CI, 6.9–13%) in Central/South
Asia. No carriers of the variant allele were found in Oceania.
The SLCO1B1*1A & SLCO1B1*1B are the haplotypes of T, and the SLCO1B1*5 & SLCO1B1*15
are the haplotypes of C alleles in SLCO1B1 gene respectively. And the prevalence of both
haplotypes globally is tabulated in table 1.3 below.
Region
T
Allelic Sum
(T) (%)
C
Allelic Sum
(C) (%)*1A (%) *1B (%) *5(%) *15(%)
Europe 56 26 82 2 16 18
America 37 39 76 - 24 24
Sub-Saharan
Africa
21 77 98 - 2 2
North Africa 34 48 82 2 16 18
Middle East 49 31 80 5 15 20
South/Central
Asia
52 39 91 - 9 9
East Asia 25 63 88 - 12 12
Oceania 34 66 100 - - 0
Table 1.3. Global distribution of the haplotypes formed by the c.388A>G and c.521T>C SNPs
(*1A, *1B, *5, *15) in SLCO1B1 gene (Pasanen M. , 2008).
Considering that these transporters play a key role in the distribution of many drugs and in the
transport of endogenous compounds, such as cholesterol and bile acids, inter-individual variability
in disease risk and drug response may be explained by the differential prevalence of genetic
variants. In spite of its relevance, some populations have not been characterized yet for this SNP.
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In the present study we examined the allelic frequencies of the SNP in SLCO1B1 gene that may
play an important role in drug disposition, in populations from three different ethnic/geographic
origins. Namely, Native Africans (Mozambican), Latin American (Colombian) and European
(Portuguese) populations which are not frequently the target of pharmacogenetic studies, and this
is an important issue when considering bridging of drug dosages and regimens used in different
populations.
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1.11. Aims of The Study
Several sequence variations have been discovered recently in the OATP1B1-encoding SLCO1B1
gene, some associated with altered transporter activity in vitro and in vivo. However, the frequency
of the SLCO1B1 gene sequence variations in individual populations have not been systematically
investigated. The objective of this study was to determine the frequencies of SLCO1B1 variant
alleles in Latin American (Colombian), Native African (Mozambican) and European (Portuguese)
populations.
1. To investigate the genotypic and allelic frequencies of the SLCO1B1exonic
polymorphismT521C (V174A) rs4149056 in populations of different ethnic backgrounds,
Latin American (Colombian), Native African (Mozambican) and European (Portuguese)
as a basis for future genetic association studies.
2. To compare our data to other populations globally
1.11.1. Specific Aims of the Study
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2. MATERIALS AND METHODS
2.1. Subjects and Study Design
A novel PCR-RFLP genotyping method was developed and optimized to analyse a polymorphic
variant of SLCO1B1 (OATP-C) gene, i.e., T521C. The DNA template was extracted from blood
samples obtained under informed consent, from populations of Colombia, Mozambique and
Portugal. 67 from Colombian, 53 from Portuguese and 61 from Mozambican healthy volunteers
were participated in the study. Colombian subjects were from the North-West region, mainly from
Antioquia and Chocó departments. This study followed the recommendations of the Declaration
of Helsinki promulgated in 1964 (http://ohsr.od.nih.gov/helsinki.php3). One blood sample was
obtained from each participant for DNA extraction. The study was fully carried out in the
Pharmacogenomics and Molecular Toxicology Laboratory, CCMAR/CBMR, Universidade do
Algarve, Faro, Portugal.
Blood sampling and genomic DNA extraction were carried out by taking 10-ml blood sample from
each participant in a tube containing ethylenediaminetetraacetic acid (EDTA) and stored at -20 oC
prior to DNA extraction. Genomic DNA was extracted with standard methods (QIAamp DNA
Blood Mini Kit; Qiagen, Hilden, Germany). Alternatively, in cases when small amounts of blood
were available, DNA was prepared using a quick protocol(Rudbeck & Dissing, 1998).
2.2. Genotyping
The reference sequences were obtained from the National Center for Biotechnology Information
(NCBI; Bethesda, MD, USA) database (http://www.ncbi.nlm.nih.gov/). Pharmacogenetic analysis
of the specific polymorphic variant of the SLCO1B1 SNP (c.T521C) analyzed in this study
(reference sequences, GenBank accession no. NC_000012.10) was performed by a polymerase
chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The reaction volume
in polymerase chain reactions (PCR) was 25 µl containing assay-specific primers, dNTPs, MgCl2,
Taq polymerase enzyme, PCR GoTaq Buffer Mix, water and genomic DNA and PCR included 40
cycles at 94oC for denaturation of the genomic DNA and activation of the Taq Polymerase
enzyme, 55oC for annealing of the primers, and 72oC for extension (Table 2.1 & 2.2). The PCR
assay was performed using Tpersonal Themocycler, Biometra, and finally digestion of amplified
products with a specific restriction endonuclease (Bsp1286l), followed by electrophoretic
separation on 2% (W/V) agarose gel, with a running time of 90 min at 80 V in 1X TAE buffer
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(Tris-acetate-EDTA buffer; 40 mM Tris, 20mM acetate, 1 mM EDTA),and visualization of the
gel-separated PCR products with Green Safe (NZYTech) staining under UV light (AlphaImager,
AlphaInnotech).
For primer design, Primer-BLAST (Ye, et al., 2012) tools were used; the sequences deposited into
the GenBank (http://www.ncbi.nlm.nih.gov/genbank/) to design pairs of allele-specific forward
primers that overlap with the SLCO1B1 allelic variant and its corresponding single reverse primers.
The primers employed in performing the PCR for the analyzed SNP, c.T521C, were Forward
primer (5’>3’); GTTAAATTTGTAATAGAAATGC, and Reverse Primer (5’>3’);
GTAGACAAAGGGAAAGTGATCATA.
Ten μl of PCR products were digested with Bsp1286I (Sdul) restriction enzyme (Thermo
Scientific), at 37 °C for 2 hours. Digested PCR products were separated by electrophoresis using
a 2 % agarose gel stained with green safe and visualized by an UV transilluminator. Some samples
were randomly selected for sequencing for confirmation.
In the 260-bp long PCR product of the T521C SNP obtained from TT homozygotes the recognition
site of the enzyme was missing, resulting in no digestion. In the samples with CC genotype the
enzyme recognition site was present, being therefore digested into 153 and 107-bp long fragments.
In samples with TC genotype, a mixed pattern was observed, with 153 -bp, 107-bp and 260-bp
fragments.
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Figure 2.1. Schematic representation of the steps of the genotyping process using PCR-RFLP.
Variables
Recommended
concentration
Optimized
Concentration
Forward Primer 0.05 – 1 M 1 M
Reverse Primer 0.05 – 1 M 1 M
dNTPs 0.02 – 0.2 mM 0.3 mM
MgCl2 0.5 – 5 mM 3 mM
PCR GoTaq Buffer Mix. 1x 1x
Taq polymerase Enzyme 1 - 2.5 U 1.5 U
Target DNA ≤ 1 µg  1 µg
Table 2.1. Optimized reaction mixture of the final PCR.
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Variables RecommendedTemperature
Optimized
Temperature
Recommended
Duration
Optimized
Time
1st DNA
Denaturation
92 – 95 oC 94 oC 2 – 5 min 2 min
2nd DNA
Denaturation
92 – 95 oC 94 oC 10 – 60 sec 40 sec
Primer
Annealing
55 – 70 oC 55 oC 30 – 60 sec 40 sec
1st Extension 72 oC 72 oC 1 min 1 min
No Cycles 20 – 40 40 - -
Final
Extension
72 oC 72oC 5 – 10 min 3 min
Cooling 4 oC - - -
Table 2.2. Optimized reaction condition of the final PCR
2.3. Hardy – Weinberg Equilibrium
The Hardy-Weinberg Law states both the allele frequencies and the genotype frequencies are
constant from generation to generation in a large, random-mating population that is not affected
by the evolutionary processes of mutation, migration, selection, finite population size (genetic
drift), or other forces, so equilibrium is reached. Thus, it is possible to calculate the expected
frequencies of genotypes in a population if the frequency of the different alleles in a sample of
population is known. The genotype frequencies are calculated using the square expansion of the
allele frequencies ((p + q)2 = p2 + 2pq + q2 = 1) (The American Phytopathological Society, 2019).
As the genotype frequencies must sum to one, summing the elements of the binomial expansion,
we obtain the expected genotype proportions among the offspring after a single generation. These
frequencies define the Hardy–Weinberg equilibrium (The American Phytopathological Society,
2019).
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In the absence of other factors, keeping allele and genotype frequencies the same, you can imagine
this process repeating over and over, generation after generation. However, a population in Hardy-
Weinberg equilibrium is, by definition, not evolving, since evolution is a change in allele
frequencies in a population over generations. Populations are usually not in Hardy-Weinberg
equilibrium (at least, not for all the genes in their genome). Instead, populations tend to evolve:
the allele frequencies of at least some of their genes change from one generation to the next.
Population geneticists often check to see if a population is in Hardy-Weinberg
equilibrium because they suspect other forces may be at work (Khanacademy, 2019).
The mechanisms that effect changes in allele frequencies are selection, mutation, migration, and
genetic drift, and when one or more of these forces are acting, the population violates Hardy-
Weinberg assumptions, and evolution occurs. The Hardy-Weinberg Theorem thus constitutes a
null model for the discipline of population genetics and is fundamental to the study of evolution
(Nature Education, 2014 ).
2.4. Statistical Analysis of Data
The method used for calculation of the Hardy-Weinberg equilibrium was described by G. H. Hardy
and W. Weinberg in 1908 (Hardy, 1908). Statistical significance (p < 0.05) was assessed by χ2 test
to compare the differences between expected and observed frequencies. Fisher’s exact test was
used to compare results in different studied populations groups.
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3. RESULTS
A total of 181 samples were genotyped for the SLCO1B1 gene variant, T521C (V174A)
rs4149056, from subjects of different ethnic groups, 67 samples from Colombian, 53 from
Mozambican and 61 from Portuguese populations. The genotypic and allelic frequencies of the
populations under study are tabulated in table 3.2 and 3.3.
Population
No. of
Subjects
Genotypes Alleles
%TT %TC %CC %T %CTT TC CC T C
Colombia 67 47 12 8 106 28 70.15 17.91 11.94 79.1 20.9
Mozambique 53 47 5 1 99 7 88.68 9.43 1.89 93.4 6.6
Portugal 61 40 16 5 96 26 65.57 26.23 8.20 78.7 21.3
Table 3.1. The genotypic and allelic distribution of the SLCO1B1 exonic polymorphism T521C
(V174A) rs4149056 in healthy Colombian, Mozambican, and Portuguese populations, analysed in
this study.
The frequency of homozygote T genotype was observed comparable (p=1.000) in Portuguese
(65.6%) and Colombian (70.2%) while the Mozambican population showed the highest frequency
among the three populations (88.7%), differing significantly from both the Portuguese (p=0.0022)
and Colombian (p=0.0017). The frequency of homozygote C genotype was generally low in all
populations. Particularly, the lowest (1.89%) was found in Mozambicans. Whereas the frequency
of heterozygote TC genotype was found to be similar in Portuguese (26.23%) and Colombian
(17.91%), it as lowest in Mozambique.
The percent allelic frequency of T and C in the T521C (rs4149056) variant was similar in both
Colombia and Portugal populations. The prevalence of the variant allele, that leads to reduced
function, corresponds to circa 20% of the analysed alleles in Portugal and Colombia, being lower
in Mozambique.
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3.1. Genotypic Frequencies for the SNP 521T>C in Different Population Studies
Table 3.2 lists the information available on the prevalence of the exonic polymorphism SLCO1B1
(OATP-C), variant T521C, from this study and the literature.
Population
No. of
Subjects.
Genotypic frequency (%)
StudyTT TC CC
Colombians 67 70.15 17.91 11.94 This Study
Mozambicans 53 88.68 9.43 1.89 This Study
Portuguese 61 65.57 26.23 8.20 This Study
Emirates 282 78.72 18.44 2.84 (Saber-Ayad, et al., 2018)
Europeans 236 69.92 25.85 4.24 (Saber-Ayad, et al., 2018)
Tanzanians 364 94.23 5.77 0.00 (Saber-Ayad, et al., 2018)
Roma 470 67.02 31.49 1.49 (Nagy, et al., 2015)
Hungarian 442 65.16 31.90 2.94 (Nagy, et al., 2015)
Finnish 468 63.89 31.84 4.27 (Santos, et al., 2012)
Brazilian 143 74.13 23.78 2.10 (Li, et al., 2012)
Indian (Singapore) 100 87.00 13.00 0.00 (Melo, et al, 2015)
Chinese (Singapore) 100 75.00 24.00 1.00 (Melo, et al, 2015)
Chinese (Han) 111 73.87 24.32 1.80 (Hubacek JA, 2015)
Malays (Singapore) 100 79.00 20.00 1.00 (Melo, et al, 2015)
Table 3.2. The genotypic frequency of the SLCO1B1 exonic polymorphism T521C (V174A)
rs4149056 in healthy Colombian, Mozambicans, and Portuguese population and other different
ethnic origins.
3.2. Allelic Frequencies for the SNP 521T>C in Different Population Studies
The allelic frequencies for the 521T>C SNP found in this study and in other populations up to date
are listed in table 3.3.
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Population
Allelic Frequency (%)
Study
T C
Colombians 79 21 This Study
Mozambicans 93 7 This Study
Portuguese 79 21 This Study
Emirates 88 12 (Saber-Ayad, et al., 2018)
Europeans 83 17 (Saber-Ayad, et al., 2018)
Tanzanians 97 3 (Saber-Ayad, et al., 2018)
Roma 83 17 (Nagy, et al., 2015)
Hungarian 81 19 (Nagy, et al., 2015)
Finnish 80 20 (Santos, et al., 2012)
Brazilian 86 14 (Li, et al., 2012)
Indian (Singapore) 94 6 (Melo, et al, 2015)
Chinese (Singapore) 87 13 (Melo, et al, 2015)
Chinese (Han) 86 14 (Hubacek JA, 2015)
Malays (Singapore) 89 11 (Melo, et al, 2015)
Table 3.3. The allelic frequencies for the SLCO1B1 exonic polymorphism T521C (V174A)
rs4149056 in healthy Colombian, Mozambicans, and Portuguese population and other different
ethnic origins.
3.3. Hardy – Weinberg Equilibrium
To evaluate if the studied populations obey the Hardy-Weinberg equilibrium, the expected
genotypic frequencies were calculated from the allelic frequencies determined experimentally, and
then compared to the observed genotypic frequencies. If, in our case, p = allelic frequency of T,
and q= allelic frequency of C, then the expected genotypic frequencies of T/T, T/C and C/C
correspond to p2, 2pq, and q2. Table 3.4 shows the results of this analysis for the populations
characterized in this study, and for the other populations previously described in the literature.
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Population Genotype Observedfrequency
Expected
frequency P-value
Colombians
TT 47 0.702 0.626
0.0009TC 12 0.179 0.331
CC 8 0.119 0.044
Mozambicans
TT 47 0.887 0.872
0.1924TC 5 0.094 0.123
CC 1 0.019 0.004
Portuguese
TT 40 0.656 0.619
0.2290TC 16 0.262 0.335
CC 5 0.082 0.045
Emirates
TT 222 0.787 0.773
0.1082TC 52 0.184 0.212
CC 8 0.028 0.015
Europeans
TT 165 0.699 0.686
0.3577TC 61 0.259 0.284
CC 10 0.042 0.029
Tanzanians
TT 343 0.942 0.943
0.8258TC 21 0.058 0.056
CC 0 0 0.001
Roma
TT 315 0.670 0.685
0.0743TC 148 0.315 0.285
CC 7 0.015 0.030
Hungarian
TT 288 0.652 0.658
0.6687TC 141 0.319 0.306
CC 13 0.029 0.036
Finnish
TT 299 0.639 0.637
0.9724TC 149 0.318 0.322
CC 20 0.043 0.041
Brazilian TT 106 0.741 0.740 0.9933
38
TC 34 0.238 0.241
CC 3 0.021 0.020
Indian (Singapore)
TT 87 0.870 0.874
0.7968TC 13 0.130 0.122
CC 0 0 0.004
Chinese (Singapore)
TT 75 0.750 0.757
0.8264TC 24 0.240 0.226
CC 1 0.010 0.017
Chinese (Han)
TT 82 0.739 0.740
0.9946TC 27 0.243 0.240
CC 2 0.018 0.019
Malays (Singapore)
TT 79 0.790 0.792
0.9792TC 20 0.200 0.196
CC 1 0.010 0.012
Table 3.4. Hardy – Weinberg Equilibrium test of SLCO1B1 exonic polymorphism; T521C
(V174A) rs4149056 in healthy Colombian, Mozambicans, and Portuguese populations and other
different ethnic origins.
The two-tailed P-value for the Colombians is less than 0.05, which indicates that there is significant
difference between the observed and expected values and therefore the analyzed sample of the
Colombian population doesn’t follow Hardy-Weinberg equilibrium. Whereas for Mozambique
and Portugal population the P-value is greater than 0.05, which means, the difference between the
expected and observed genotypic frequencies is not significant and the analyzed sample of the two
populations follows Hardy-Weinberg equilibrium. The same can be said for all other populations
previously characterized in the literature.
3.4. Comparison of the Populations Analyzed with Other Populations
To evaluate the similarity between the populations analysed in the study to each other, and to
others previously studied, the distribution of alleles for the 521T>C SNP in the different
populations were compared using a table of contingency. The results are shown in table 3.5 below.
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Colombian Mozambican Portuguese
Colombian - 0.0017* 1.0000
Mozambican 0.0017* - 0.0022*
Portuguese 1.0000 0.0022* -
Emirates 0.0115* 0.1296 0.0128*
Europeans 0.3113 0.0044* 0.2921
Tanzanians 0.0001* 0.0743 0.0001*
Roma 0.3325 0.0032* 0.2588
Hungarian 0.5581 0.0010* 0.5399
Finnish 0.8192 0.0003* 0.8109
Brazilian 0.0878 0.0536 0.0779
Indian (Singapore) 0.0001* 1.0000 0.0002*
Chinese (Singapore) 0.0684 0.1201 0.0608
Chinese (Han) 0.1055 0.0643 0.0953
Malays (Singapore) 0.0183* 0.3047 0.0152*
* p<0.05; statistically significant difference in observed frequencies
Table 3.5. Comparison of the allele distribution observed in Colombian, Mozambican and Portugal
population against different populations by their two-tailed P value
From the above contingency table, the frequencies observed in Colombians are different from the
ones observed in Mozambicans, Emirates, Tanzanians, Indians (Singapore), and Malays
(Singapore) populations, and that these differences are statistically significant (p<0.05). However,
frequencies observed in Colombian are similar with those found in Portuguese, Europeans, Roma,
Hungarians, Finnish, Brazilians, Chinese (Singapore) and Chinese (Han), since the observed
differences are not statistically significant (p>0.05).
The frequencies observed in Mozambicans are significantly different from the ones observed in
Colombians, Portuguese, Europeans, Roma, Hungarians, and Finnish populations (p<0.05).
However, the distribution in Mozambicans is similar with Emirates, Tanzanians, Brazilians,
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Indians (Singapore), Chinese (Singapore), Chinese (Han) and Malays (Singapore) (p>0.05). The
Portuguese population showed frequencies that are different from the ones observed in
Mozambicans, Emirates, Tanzanians, Indians (Singapore) and Malays (Singapore), populations,
and that these differences are statistically extremely significant (p<0.05). However, frequencies
observed in Portugal are similar with Colombians, Europeans, Roma, Hungarians, Finnish,
Brazilians, Chinese (Singapore) and Chinese (Han).
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4. DISCUSSION
The disposition of many drugs such as antidislipidemic, antitumor or antidiabetic has been
demonstrated to be affected by the chemical properties and structural conformations of influx
transporters. This association in turn affects efficacy and/or safety of the drugs. The variability in
the response to a large range of drugs may be derived from the pharmacogenetic diversity of these
transporters. Therefore, evaluation of SNP frequencies among different populations with variable
ethnic background will certainly be very useful as a tool to optimize therapeutics according to
variable predicted pharmacokinetics. Many studies reported that statin-induced myopathy is
significantly associated with the SCLO1B1 influx transporter gene c.521T>C (rs4149056)
polymorphism. We analyzed the genotypic and allelic frequencies of this polymorphism in
Colombian, Mozambican, and Portuguese subjects.
At the best of our knowledge, this study is the first to explore the prevalence of SLCO1B1 gene
polymorphism T521C (rs4149056), in these three populations. In our study, we found that the most
dominant genotype in all populations under study was the homozygous T/T, 70.15%, 88.68%, and
65.57% respectively. Individuals with the homozygote variant genotype C/C, which are predicted
to show the most significant clinical impact, were found at frequencies of 8.2%, 1.9% and 11.9%
in Portuguese, Mozambicans and Colombians, respectively.
The highest frequency of the reference T allele was found in Mozambique (93%) is in agreement
with a previous study in another African ancestry, Tanzanians (97%) (Saber-Ayad, et al., 2018),
and Indian (Singapore) (94%) and Malays (Singapore) (89%) (Melo, et al., 2015). However, this
allelic frequency is relatively higher than Colombian (79%) and Portuguese (79%) subjects (this
study), which is also consistent with another studies in Europeans (Germany) (83%) (Saber-Ayad,
et al., 2018), Roma (83%), Hungarian (81%) (Nagy, et al., 2015), Austrian (82.3%) (Enko, et al.,
2018) and Finnish populations (80%) (Santos, et al., 2012). This discrepancy may be caused by
differences in sample sizes between these studies and in the origin of the samples. The differences
observed in the frequencies among Mozambique, Colombia and Portugal populations clearly
indicates a possible therapeutic failure of the “one-dose-fits-all” approach among these
populations.
Recent knowledge suggests that the SLCO1B1 polymorphisms may have particularly important
effects on the pharmacokinetic profile of statin drugs (e.g., atorvastatin) and most studies are
mainly focused on the influence of c.521T > C polymorphism. One study shows that higher Cmax,
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AUC0-48h, AUC0-∞, MRTexpo and lower Tmax, Vd and CL for atorvastatin in in SLCO1B1 c.521CC
compared to the other genotype group of the c.521T > C (Daka, et al., 2015). In another study,
significantly larger (144%) mean AUC 0-48h has been observed in subjects (n = 4) with SLCO1B1
c.521CC genotype than the subjects (n = 16) with c.521TT (reference) genotype and 61% larger
than the subjects (n = 12) with c.521TC genotype. Theoretically speaking, these findings attest
that reduced OATP1B1 function could reduce the clearance of atorvastatin, because of the
decreased entry into the liver, the main site of metabolism and elimination of atorvastatin (Pasanen,
et al., 2007).
Numerous other clinical studies have also confirmed that subjects, who are carriers of SLCO1B1
521C allele, had increased plasma concentrations of other OATP1B1 substrates (e.g. pravastatin
and repaglinide) compared to the subjects who were reference homozygotes (SLCO1B1 521T
allele) (Aquilante, et al., 2008) (Kivistö & Niemi, 2007) (Niemi, et al., 2005a) (Kalliokoski, et al.,
2008b).
Generally, the myopathy risk for statin users carrying the homozygous C/C genotype is 17-fold
higher when compared to the carriers of reference homozygotes, while heterozygous TC subjects
show a 5-fold increase in risk (SNPedia: a wiki supporting personal genome annotation,
interpretation and analysis, 2019).
The fact that the relatively high frequencies of the low-activity variants in the European
(Caucasian) ancestry signposts higher risk of statin induced side effects. Similarly, Ho et al. 2007
reported that European-Americans have significantly higher plasma pravastatin AUCs than
African Americans (Ho, et al., 2007). This polymorphism was also associated with an increased
risk of cardiovascular adverse effects in individuals taking simvastatin (Voora, et al., 2009).
In the other side, the SLCO1B1 c.521CC variant genotype was associated with an increased
baseline cholesterol synthesis rate. Higher plasma desmosterol to cholesterol ratios and higher
plasma desmosterol concentrations had been observed in individuals with the c.521CC genotype
than those with the c.521TT genotype (Pasanen M. , 2008). This functional link between
cholesterol homeostasis and OATP1B1 could be through bile acid homeostasis, as the regulation
of bile acid synthesis and cholesterol homeostasis is tightly linked, with OATP1B1 playing a major
role in the uptake of certain bile acids. The bile acid concentration in the liver could be decreased
as a result of impaired activity of OATP1B1 by limiting the access of bile acids from the portal
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blood into the liver. Basolateral OATP transporters are thought to be mediators of the
approximately 20% hepatic uptake of bile acids.
Therefore, the identification and characterization of these genetic variations may help in the
development of SLCO1B1 genotype-based prescription or more personalized drug therapies to
achieve the benefits of statin therapy more safely and effectively.
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5. CONCLUSIONS
Genetic variants of influx transporters are of key relevance, as it has become evident that these
influx transporter proteins play a central role in drug disposition, contributing to variable efficacy
and/or safety, as well as in the control of endogenous mediators such as cholesterol, bile acids or
vasodilators. The pharmacogenetic results from the current study and many studies in the literature
suggests that the influx transporter SLCO1B1 gene SNPs shows very high population specificity.
The functionally detrimental homozygous variant c.521CC genotype is relatively more prevalent
in Caucasians than in other African and Asian origin ethnic backgrounds. As a result, subjects
(mainly Caucasians) with the homozygous variant c.521CC genotype had shown considerably
higher plasma concentrations of statins than those with the c.521TT (reference) genotype.
SLCO1B1 genotyping may have clinical value for adjusting doses of statin therapy to reduce the
risk of myopathy development and to aid in the prediction of differential susceptibility to adverse
effects. The results obtained in this study may contribute to variable disease risk and therapeutic
outcomes in individuals from Colombia, Mozambique and Portugal.
Therefore, the investigation of clinically relevant polymorphisms such as SLCO1B1 gene,
especially, in the populations substantially less characterized for pharmacogenetic variability is
very important, since more information is needed before an adequate bridging of therapeutic
dosages and regimens.
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